Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLEC | Q15149 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903190 | 0.82 | L3MBTL1 (0.56) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL5248339 | 0.81 | L3MBTL1 (0.55) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL5245595 | 0.80 | CACNA1G (0.39) | MAPTALDH1A1GAATHRBCYP1A2 | |
| SCHEMBL31737574 | 0.80 | IDO1 (0.52) | L3MBTL1MAPTALDH1A1GAAKDM4E | |
| SCHEMBL809192 | 0.80 | IDO1 (0.52) | L3MBTL1MAPTALDH1A1GAAKDM4E | |
| SCHEMBL3149687 | 0.78 | L3MBTL1 (0.60) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL5254664 | 0.77 | L3MBTL1 (0.64) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL31054 | 0.77 | L3MBTL1 (0.84) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL4075277 | 0.76 | L3MBTL1 (0.58) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL2908416 | 0.76 | L3MBTL1 (0.58) | L3MBTL1MAPTNPSR1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223916-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | Eli Lilly and Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1682523-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1729754-B1 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1369405-B1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL CO (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1729754-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-6861566-B2 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1369405-A1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | L3MBTL1 3071/4885MAPT 169/4885NPSR1 91/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | L3MBTL1 3499/4885MAPT 1246/4885NPSR1 82/4885 |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | CYP1B1, CBR1, CYP1A1 | L3MBTL1 1663/4885MAPT 4627/4885NPSR1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.